Lamivudine + Tenofovir disoproxil fumarate + Efavirenz Tablet

Lamivudine + Tenofovir disoproxil fumarate + Efavirenz tablet is a fixed-dose combination antiretroviral medicine used in the management of human immunodeficiency virus (HIV) infection. This combination works through multiple mechanisms to inhibit viral replication, helping reduce HIV viral load and support long-term disease control under medical supervision.

This once-daily tablet is commonly prescribed to simplify HIV treatment regimens and improve patient adherence. By combining three well-established antiretroviral agents into a single tablet, this product supports consistent dosing and effective viral suppression when taken as directed by a healthcare professional.

This product follows recognized quality and safety standards to support consistent therapeutic performance. As a trusted pharmaceutical product, the Lamivudine (300 mg) + Tenofovir Disoproxil Fumarate (300 mg) + Efavirenz (600 mg) tablet offers pharmaceutical-grade quality and plays an important role in modern pharmaceutical antiretroviral treatment strategies.

Product Features

• Fixed-dose combination antiretroviral tablet
• Contains Lamivudine 300mg, Tenofovir DF 300mg, and Efavirenz 600 mg.
• Used for effective HIV infection management
• Once-daily oral tablet for simplified dosing
• Pharmaceutical-grade quality standards

How It Helps

• Helps suppress HIV viral replication
• Supports long-term control of HIV infection
• Assists in maintaining immune system strength
• Reduces the risk of HIV disease progression
• Improves treatment adherence with single-tablet therapy